Added to YB: 2026-09-15
Pitch date: 2026-09-12
SPRY [neutral]
ARS Pharmaceuticals, Inc.
-6.25%
current return
Author Info
No bio for this author
Company Info
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally.
Market Cap
$473.4M
Pitch Price
$4.80
Price Target
N/A
Dividend
N/A
EV/EBITDA
-2.33
P/E
-2.19
EV/Sales
4.29
Sector
Biotechnology
Category
growth
Biotech Conference Coverage Day 4 Session 2 - ARS Pharmaceuticals, Inc.
SPRY (quick overview): ARS Pharmaceuticals, at roughly $5.06-$5.28, is a commercial-growth and potential strategic-acquisition candidate: NEFFY targets the gap between 20M diagnosed allergy patients and only 3M annual epinephrine prescriptions. Share is 8% in sales-force-targeted territories versus 1% in uncovered areas, but adoption should be gradual and depends on prescribing conversion and payer access; ARSO2 offers a second opportunity, with interim CSU data expected in Q1 2027.
Read full article (2 min)